Search

everythinglearnresearchcommunity

for

Search:↓

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

A 19-year-old is using oral dutasteride, topical minoxidil, and dermastamping to address hair loss and enhance facial hair growth, experiencing minimal side effects and increased body hair. They report positive results in hairline thickness and temple closure.

The user is seeking recommendations for topical saw palmetto and pumpkin seed oil products to treat early male pattern baldness and is considering different options available online. They are specifically asking which saw palmetto product to choose between two provided links.

User reports baby hairs appearing 4 months into finasteride treatment. Current regimen includes finasteride, rosemary oil, topical melatonin, nizoral shampoo, hair supplements, scalp massages, and dermarolling.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

A 23-year-old user shares their hair regrowth journey, questioning if genetics or other factors are at play. They use Rogaine, finasteride, vitamin B12, biotin, Thera M Plus, and derma stamping, and seek advice on their regimen and hair growth patterns.

A user shared their hair regrowth journey from Norwood 7 at age 22 using oral minoxidil 10mg, dutasteride 0.5mg, and RU58841 70mg, along with a recent hair transplant. They experienced significant progress and discussed potential side effects, particularly with oral minoxidil, and plan to update on further growth.

The user had a hair transplant in 2021 with 1600 grafts and is currently using finasteride, minoxidil, biotin, and collagen. They are considering another transplant in Turkey to address a bald spot and improve coverage in the front and middle.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.

The user has been using Minoxidil for 2 months and Finasteride for 1 month to address hair loss, particularly at the temples. They are questioning whether the new small hairs are facial hairs or new scalp hair.

An 18-year-old is using finasteride for hair loss prevention despite having a healthy hairline. Opinions are mixed, with some advising against its use at his age and others supporting his proactive approach.

A user, 42 M, NW 5-6, used oral Dutasteride, Minoxidil, RU58841 topical, micro needling, Nizoral shampoo, saw palmetto gummies, vitamin D gummies, and scalp massages for 2 months. They noticed many small light hairs on previously bald areas and are questioning if these will darken or remain vellus hairs.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A woman with hair loss discovered she has thyroid cancer, which was found during an MRI and confirmed with an ultrasound. She advises others with symptoms to see a doctor and shares that her cancer was detected after her dog sniffed her neck and she experienced neck pain.

A 19-year-old plans to start Dutasteride 0.5mg three times a week to combat genetic alopecia and preserve hair density, with concerns about potential shedding before prom. Users suggest starting the treatment after prom to avoid shedding, and provide advice on where to purchase the medication.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

A 20-year-old female with PCOS is experiencing hair loss and excessive facial hair. She is using ketoconazole and caffeine shampoos, microneedling, and considering anti-androgens like finasteride, but is cautious about minoxidil due to facial hair concerns.

User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.

A user experiencing diffuse thinning since age 18 describes their hair as unhealthy, dry, thin, and hard, with texture changes cycling between good and bad every few weeks. They are not on any medication, only taking vitamins and supplements.

An 18-year-old started taking finasteride for early-stage hair loss, prescribed by a dermatologist who advised against waiting due to potential follicle loss. The conversation includes differing opinions on starting finasteride early, with some users sharing personal experiences and concerns about potential side effects.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

A 19-year-old is experiencing hair loss and has been using Rogaine for a month and finasteride for four days without improvement, while also experiencing testicular discomfort. They are concerned about losing hair density and potential DUPA, comparing their situation to their father's hair condition.

A 19-year-old male shared his 10-month progress using finasteride, starting at 0.25mg and increasing to 1.25mg daily, noting new hair growth at the temples. He experienced a significant shed at 6 months but reported no side effects from increasing the dosage.